Amneal Pharmaceuticals Inc. (AMRX)
Summary
5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low
COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns
Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.
Amneal Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 24,678 | $375,725.75 | $452,100.96 | $76,375.21 | 20.33% |
 Curtis Ellergodt Rothschild Investment LLC | 4,266 | $26,526.11 | $78,153.12 | $51,627.01 | 194.63% |
| PER Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc. | 56,150 | $698,000 | $991,609 | $293,609 | 42.06% |
| NA Nizar Araji National Bank Of Canada /FI/ | 2,624 | $16,940.26 | $47,625.6 | $30,685.34 | 181.14% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 1,242 | $12,432.42 | $22,529.88 | $10,097.46 | 81.22% |
Amneal Pharmaceuticals Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Chris Schott JP Morgan | 6,629.03 | $119,256.23 | $115,809.14 | -$3,447.09 | -2.89% |
Amneal Pharmaceuticals Inc. (AMRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Amneal Pharmaceuticals Inc. ever had a stock split?
Amneal Pharmaceuticals Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Chirag K. Patel CEO | NASDAQ (NGS) Exchange | 03168L105 CUSIP |
| US Country | 8,700 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Amneal Pharmaceuticals, Inc., a comprehensive player in the pharmaceutical industry, engages in the development, manufacturing, marketing, and distribution of a wide range of pharmaceutical products on a global scale. With its foundation laid in 2002, and initially called Atlas Holdings, Inc., the company took on its current identity in 2018, signaling a strategic realignment towards expanding its pharmaceutical endeavors. Headquartered in Bridgewater, New Jersey, Amneal has strategically divided its operations into three main segments: Generics, Specialty, and AvKARE, each addressing distinct aspects of healthcare needs. Their portfolio spans generics, injectables, biosimilars, and specialty branded products, catering to a myriad of medical conditions and patient requirements worldwide.
Products and Services
- Generics Segment:
Comprehensive in scope, this segment delivers an array of product forms including immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory treatments, biosimilars, ophthalmics, films, transdermal patches, and topicals. Catering to a wide range of health conditions, this division underscores Amneal's commitment to accessibility and affordability in healthcare.
- Specialty Segment:
Focused on central nervous system (CNS) disorders such as Parkinson's disease and endocrine disorders, this segment offers specialized pharmaceuticals such as Rytary, an oral capsule formulation of carbidopa-levodopa for Parkinson's and related conditions; Unithroid, which addresses hypothyroidism; and IPX203, a product in the pipeline aimed at enhancing Parkinson's disease management. This segment epitomizes Amneal's dedication to tackling complex health issues with innovative solutions.
- AvKARE Segment:
Targeting governmental agencies, the Department of Defense, and the Department of Veterans Affairs, AvKARE provides pharmaceuticals, medical and surgical products, and services. This includes the distribution of pharmaceuticals and vitamins in bottle and unit dose formats under the AvKARE and AvPAK brands. This segment strengthens Amneal's footprint in the institutional and government sectors, illustrating a broad-based approach to healthcare provisioning.
